BACKGROUND: Some forms of gastric intestinal metaplasia (GIM) may be precancerous but the cellular phenotype that predisposes to gastric carcinogenesis is not well characterised. Mucin staining, as a means of differentiating GIM, is difficult. A monoclonal antibody, mAb Das-1 (initially called 7E(12)H(12)), whose staining is phenotypically specific to colon epithelium, was used to investigate this issue. METHODS: Using mAb Das-1, by a sensitive immunoperoxidase assay, we examined histologically confirmed GIM specimens from two countries, the USA and Japan. A total of 150 patients comprised three groups: group A, GIM (fields away from the cancer area) from patients with gastric carcinoma (n=60); group B, GIM with chronic gastritis (without gastric carcinoma) (n=72); and group C, chronic gastritis without GIM (n=18). RESULTS: Fifty six of 60 (93%) patients with GIM (both goblet and non-goblet metaplastic cells) from group A reacted intensely with mAb Das-1. Cancer areas from the same 56 patients also reacted. In contrast, 25/72 (35%) samples of GIM from patients in group B reacted with mAb Das-1 (group A v B, p<0.0001). None of the samples from group C reacted with the mAb. CONCLUSIONS: Reactivity of mAb Das-1 is clinically useful to simplify and differentiate the phenotypes of GIM. The colonic phenotype of GIM, as identified by mAb Das-1, is strongly associated with gastric carcinoma.
BACKGROUND: Some forms of gastric intestinal metaplasia (GIM) may be precancerous but the cellular phenotype that predisposes to gastric carcinogenesis is not well characterised. Mucin staining, as a means of differentiating GIM, is difficult. A monoclonal antibody, mAb Das-1 (initially called 7E(12)H(12)), whose staining is phenotypically specific to colon epithelium, was used to investigate this issue. METHODS: Using mAb Das-1, by a sensitive immunoperoxidase assay, we examined histologically confirmed GIM specimens from two countries, the USA and Japan. A total of 150 patients comprised three groups: group A, GIM (fields away from the cancer area) from patients with gastric carcinoma (n=60); group B, GIM with chronic gastritis (without gastric carcinoma) (n=72); and group C, chronic gastritis without GIM (n=18). RESULTS: Fifty six of 60 (93%) patients with GIM (both goblet and non-goblet metaplastic cells) from group A reacted intensely with mAb Das-1. Cancer areas from the same 56 patients also reacted. In contrast, 25/72 (35%) samples of GIM from patients in group B reacted with mAb Das-1 (group A v B, p<0.0001). None of the samples from group C reacted with the mAb. CONCLUSIONS: Reactivity of mAb Das-1 is clinically useful to simplify and differentiate the phenotypes of GIM. The colonic phenotype of GIM, as identified by mAb Das-1, is strongly associated with gastric carcinoma.
Authors: N Matsukura; K Suzuki; T Kawachi; M Aoyagi; T Sugimura; H Kitaoka; H Numajiri; A Shirota; M Itabashi; T Hirota Journal: J Natl Cancer Inst Date: 1980-08 Impact factor: 13.506
Authors: Jochen K M Lennerz; Seok-Hyung Kim; Edward L Oates; Won Jae Huh; Jason M Doherty; Xiaolin Tian; Andrew J Bredemeyer; James R Goldenring; Gregory Y Lauwers; Young-Kee Shin; Jason C Mills Journal: Am J Pathol Date: 2010-08-13 Impact factor: 4.307
Authors: Koushik K Das; Hong Xiao; Xin Geng; Carlos Fernandez-Del-Castillo; Vicente Morales-Oyarvide; Ebubekir Daglilar; David G Forcione; Brenna C Bounds; William R Brugge; Martha B Pitman; Mari Mino-Kenudson; Kiron M Das Journal: Gut Date: 2013-11-25 Impact factor: 23.059
Authors: Koushik K Das; Jeffrey W Brown; Carlos Fernandez Del-Castillo; Tiffany Huynh; Jason C Mills; Yoko Matsuda; Kiron M Das; Mari Mino-Kenudson Journal: Hum Pathol Date: 2021-01-30 Impact factor: 3.466
Authors: Athanasios Koulis; Natasha Di Costanzo; Catherine Mitchell; Stephen Lade; David Goode; Rita A Busuttil; Alex Boussioutas Journal: BMC Gastroenterol Date: 2022-04-21 Impact factor: 2.847